Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
08
08
2022
accepted:
19
01
2023
medline:
21
8
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused to a human IgG1 monoclonal antibody blocking programmed death ligand 1, was evaluated in patients with locally advanced/metastatic chemorefractory biliary tract cancers. This multicenter, single-arm, open-label, phase 2 study (NCT03833661) enrolled adults with locally advanced or metastatic biliary tract cancer that was intolerant to or had failed first-line systemic platinum-based chemotherapy. Patients received 1200 mg bintrafusp alfa intravenously Q2W. The primary endpoint was confirmed objective response according to Response Evaluation Criteria in Solid Tumors 1.1 assessed by IRC. Secondary endpoints included duration of response, durable response rate, safety, progression-free survival, and overall survival.Between March 2019 and January 2020, 159 patients were enrolled. Median follow-up was 16.1 (range, 0.0-19.3) months; 17 patients (10.7%; 95% CI: 6.4%-16.6%) achieved an objective response. Median duration of response was 10.0 (range, 1.9-15.7) months; 10 patients (6.3%; 95% CI: 3.1%-11.3%) had a durable response (≥6 mo). Median progression-free survival was 1.8 months (95% CI: 1.7-1.8 mo); median overall survival was 7.6 months (95% CI: 5.8-9.7 mo). Overall survival rates were 57.9% (6 mo) and 38.8% (12 mo). Grade ≥3 adverse events occurred in 26.4% of patients, including one treatment-related death (hepatic failure). Frequent grade ≥3 adverse events included anemia (3.8%), pruritus (1.9%), and increased alanine aminotransferase (1.9%). Although this study did not meet its prespecified primary endpoint, bintrafusp alfa demonstrated clinical activity as second-line treatment in this hard-to-treat cancer, with durable responses and a manageable safety profile.
Sections du résumé
BACKGROUND AND AIMS
Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused to a human IgG1 monoclonal antibody blocking programmed death ligand 1, was evaluated in patients with locally advanced/metastatic chemorefractory biliary tract cancers.
APPROACH AND RESULTS
This multicenter, single-arm, open-label, phase 2 study (NCT03833661) enrolled adults with locally advanced or metastatic biliary tract cancer that was intolerant to or had failed first-line systemic platinum-based chemotherapy. Patients received 1200 mg bintrafusp alfa intravenously Q2W. The primary endpoint was confirmed objective response according to Response Evaluation Criteria in Solid Tumors 1.1 assessed by IRC. Secondary endpoints included duration of response, durable response rate, safety, progression-free survival, and overall survival.Between March 2019 and January 2020, 159 patients were enrolled. Median follow-up was 16.1 (range, 0.0-19.3) months; 17 patients (10.7%; 95% CI: 6.4%-16.6%) achieved an objective response. Median duration of response was 10.0 (range, 1.9-15.7) months; 10 patients (6.3%; 95% CI: 3.1%-11.3%) had a durable response (≥6 mo). Median progression-free survival was 1.8 months (95% CI: 1.7-1.8 mo); median overall survival was 7.6 months (95% CI: 5.8-9.7 mo). Overall survival rates were 57.9% (6 mo) and 38.8% (12 mo). Grade ≥3 adverse events occurred in 26.4% of patients, including one treatment-related death (hepatic failure). Frequent grade ≥3 adverse events included anemia (3.8%), pruritus (1.9%), and increased alanine aminotransferase (1.9%).
CONCLUSIONS
Although this study did not meet its prespecified primary endpoint, bintrafusp alfa demonstrated clinical activity as second-line treatment in this hard-to-treat cancer, with durable responses and a manageable safety profile.
Identifiants
pubmed: 36999533
doi: 10.1097/HEP.0000000000000365
pii: 01515467-990000000-00358
pmc: PMC10442127
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunologic Factors
0
Banques de données
ClinicalTrials.gov
['NCT03833661']
Types de publication
Multicenter Study
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
758-770Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
ESMO Open. 2022 Feb;7(1):100377
pubmed: 35093741
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
J Gastrointest Oncol. 2016 Oct;7(5):797-803
pubmed: 27747093
Cancer. 2021 Jul 1;127(13):2238-2250
pubmed: 33748947
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
Chin Clin Oncol. 2016 Oct;5(5):61
pubmed: 27829275
Ann Oncol. 2014 Dec;25(12):2328-2338
pubmed: 24769639
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815
pubmed: 34358484
Nat Rev Drug Discov. 2012 Oct;11(10):790-811
pubmed: 23000686
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Am Soc Clin Oncol Educ Book. 2016;35:e194-203
pubmed: 27249723
Cell Death Discov. 2017 Nov 27;3:17069
pubmed: 29188076
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461347
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
JAMA Oncol. 2020 Sep 1;6(9):1405-1409
pubmed: 32729929
Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
Biol Res. 2015 May 21;48:26
pubmed: 25993985
JAMA Oncol. 2021 Nov 01;7(11):1669-1677
pubmed: 34554208
PLoS One. 2017 Sep 5;12(9):e0183932
pubmed: 28873435
Clin Cancer Res. 2020 Jul 1;26(13):3202-3210
pubmed: 32299818
Ann Oncol. 2022 Sep;33(9):929-938
pubmed: 35680043
Cancers (Basel). 2020 May 14;12(5):
pubmed: 32423017
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722188
J Gastrointest Oncol. 2017 Apr;8(2):293-301
pubmed: 28480068
PLoS One. 2014 Mar 11;9(3):e90353
pubmed: 24618589
Lancet Oncol. 2021 Nov;22(11):1560-1572
pubmed: 34656226